Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIVERSAL2: pharmacokinetics, safety and acceptability of darunavir/ritonavir in children living with HIV
PACTR202405769820746Phase 2Not yet recruiting
- Sponsor
- Penta Foundation
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by Penta Foundation. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
darunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202405769820746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405769820746.